Immunotherapy plus chemo shows promise against tough pancreatic cancer

This study tested whether adding an immunotherapy drug (anti-PD-1 antibody) to standard chemotherapy can help people with locally advanced or borderline resectable pancreatic cancer. About 392 participants were randomly assigned to receive either chemo alone or chemo plus the immunotherapy. The goal was to see if the combination could delay cancer growth or improve survival. Pancreatic cancer is very hard to treat, so researchers are looking for better options.